Progesterone Market Overview
The Progesterone Market Size is estimated to reach $2,127.4 million by 2027 and it is poised to grow at a CAGR of 12.9% over the forecast period of 2022-2027. Progesterone is a hormone that naturally occurs in the body. It is produced by the ovaries and one of its critical applications is supporting pregnancy. Gonadotropin-releasing hormone allows for the making of estrogen, progesterone and testosterone. Progesterone and estrogen levels have a strong influence on menstrual periods and menopausal symptoms in the latter half of life. Progesterone is actively given as a daily/bi-weekly prescription drug for infertility, abnormal uterine bleeding, amenorrhea and other forms of hormone therapy for cancer. As per a study published in a leading U.S. medical magazine, nearly 5% of menstruating women in the U.S. experience 3 months of a secondary form of amenorrhea which can be ramified by progesterone. The growing role of pipeline drugs supported by the rising awareness of such products in the field would proliferate the Progesterone Industry during the forecast period of 2022-2027.
Progesterone Market Report Coverage
The Report: “Progesterone Market Forecast (2022-2027)" by IndustryARC, covers an in-depth analysis of the following segments in the Progesterone Market.
- Geographically, North America held a dominant market share in 2021. It is due to significant collaborative efforts undertaken to enhance the overall capabilities and high medical standards which impel a strong position. However, Asia-Pacific is estimated to offer lucrative opportunities in the projected period owing to higher medical awareness, a rise in knowledge about the female body and a significant healthcare boost.
- A rising incidence of abnormal uterine bleeding and uterine and breast cancer cases, subjugated by amenorrhea, has driven the market positively. However, a lack of awareness of the availability of products and Progesterone therapy in developing markets impedes market growth.
- A detailed analysis of the strengths, weaknesses, opportunities and threats would be provided in the Progesterone Market Report.
Progesterone Market - Market Share (%) by region, 2021.
For More Details on This Report - Request for Sample
Progesterone Market Segment Analysis - by Product Type
The Progesterone Market, based on product types, can be further segmented into Natural and Synthetic Progesterone. The Natural Progesterone segment held a dominant market share and is estimated to be the fastest-growing one, with a CAGR of 13.7% over the forecast period of 2022-2027. Natural progesterone-based products include combination drugs, primarily made from soybeans or a wild-inedible Mexican yam known as Dioscorea villosa. Some of the predominant reasons for the upliftment and growth of natural products are the downturn studies published for counter-synthetic. Its evaluations have revealed that it can play a role in developing cancers. Natural progesterone-based products have been studied to generate the largest number of prescriptions. Drugs, such as Crinone and Prometrium, are the major contributors to its revenue. Moreover, as per Clinical Calc-Drug Database, nearly 3.61 million prescriptions were filled for Progesterone medicine, which was nearly 20% higher than in 2019 levels.
Progesterone Market Segment Analysis - by Application
The Progesterone Market, based on the application, can be further segmented into Menopause, Abnormal Uterine Bleeding, Uterine and Breast Cancer, Contraception, Hyperplastic Precursor Lesions, Pregnancy Assistance and Others. The Menopause segment held a dominant market share in 2021. It is due to the strong presence of women between the age of 45 and 59 as well as the strong ramification benefits progesterone offers to these women. This helps reduce the cases of hot flashes, night sweats and other side effects. As per NCBI, approximately 75-80% of menopausal women experience hot flashes. However, Pregnancy Assistance is estimated to be the fastest-growing segment, with a CAGR of 14.4% over the forecast period of 2022-2027. It is due to a trend of following a delayed years pregnancy that reduces the luteinizing hormone effect, thereby causing troubles in conceiving and maintaining pregnancy throughout the term. Progesterone therapy aids in countering both the said conditions with ease.
Progesterone Market Segment Analysis - by Geography
The Progesterone Market, based on geography, can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant share of 41% in 2021. It is due to a higher medical term awareness in the countries of the United States and Canada. Furthermore, the region has an increasing number of issues in women suffering from various conditions or factors which reduce the chances of being pregnant. As per NIA, nearly 1.3 million women in the U.S. experience menopause each year, which boosts the market growth of progesterone therapy. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2022-2027. It is due to the uprising of western trends in primitive societies that are boosted by growing medical infrastructure support in countries such as India and other parts of South-East Asia along with rising disposable incomes.
Progesterone Market Drivers
Rising cases of Amenorrhea, Breast and Uterine Cancer and AIDS along with Other Conditions:
Amenorrhea is the condition in which a woman faces an absence of one or more menstrual periods. As per NCBI, 3-5% of adult women, in general, throughout the globe face the following problem. Hormone therapy is only used for breast cancers that are found to have receptors for the naturally occurring hormones estrogen or progesterone. It reduces the chances of cancer returning post-surgery. As per the American Cancer Society, breast cancer is about 30% of all new female cancer cases registered in the U.S. each year, curating 287,000 cases yearly in the country. In the general population, progesterone supplementation is widely used, is well tolerated and is considered safe for HIV-Positive Pregnant Women. Due to these reasons, the market has registered strong growth.
The Growing Infertility Rates across Developed and Developing Countries:
Progesterone plays a critical role in infertility treatment, as the hormone is key in becoming pregnant and maintaining pregnancy throughout the months. Doctors prescribe progesterone therapy in those who have suffered a recurrent miscarriage, among other reasons. As per WHO's headline, infertility has been a global health issue and the available data suggests that around 48 million couples and 186 million individuals worldwide have infertility. Critically, infertility rates across the globe vary, offering unique opportunities to marketers. Within the EU, the fertility rate stood at 1.50 (Eurostat-2020). However, the fertility rate is 1.70 in the U.S. (World Bank-2019). However, a general downturn in the fertility rates would continue to propel the market.
Progesterone Market Challenges
Lack of Awareness about Progesterone Therapy along with Its Costs and Side Effects associated with It:
The awareness about this form of therapy runs low, especially in the developing and underdeveloped regions of the world. This results in lower sales of the product. Furthermore, cases of blood clothing have been reported in patients who have continued to rely on progesterone for reasons concerned. Progesterone (synthetic) has been linked to increased breast cancer risk. However, the role of endogenous progesterone in breast physiology and carcinogenesis is defined less clearly. As per various online sellers, the cost of a monthly prescription for oral HRT (Progesterone) runs between $130 and $240, imposing significant cost-related pressures on the market.
Progesterone Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Progesterone Industry. The top 10 companies in the Progesterone market are:
- ALKEM Labs
- Aquatic Remedies Ltd
- Blubell Pharma
- Cadila Pharmaceuticals
- Cipla Ltd
- Estrellas Life Sciences Ltd
- Lupin Ltd
- Teva Pharmaceuticals
- In September 2022, Scottish Medicines Consortium (SMC) accepted the use of BIJUVE (1mg Estradiol/100mg Progesterone) for use across the NHS in the region. Bijuve® is the first and only body-identical hormone replacement therapy (HRT), indicated for estrogen deficiency symptoms in postmenopausal women.
- In September 2022, A new scientific paper and recent advances assured that Hormone therapy can help relieve menopause symptoms such as hot flashes, night sweats, sleep disturbances, vaginal issues, sexual problems and loss of bone density.
Report Code: HCR 0597
Report Code: HCR 0222
Report Code: HCR 0629
For more Lifesciences and Healthcare Market reports, please click here